4 554

Cited 39 times in

Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma

DC Field Value Language
dc.contributor.author성진실-
dc.contributor.author윤홍인-
dc.contributor.author이익재-
dc.contributor.author한광협-
dc.date.accessioned2015-01-06T17:09:03Z-
dc.date.available2015-01-06T17:09:03Z-
dc.date.issued2014-
dc.identifier.issn0171-5216-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99431-
dc.description.abstractAIM: To investigate whether image-guided intensity-modulated radiation therapy (IG-IMRT) improves survival in hepatocellular carcinoma (HCC) relative to 3-dimensional conformal radiotherapy (3D-CRT). METHODS: Between 2006 and 2011, 187 HCC patients treated with definitive RT were reviewed. Median age was 53(range 51-83). All patients were stage III or IV-A. Concurrent chemoradiation was received by 178 patients (95.2 %). Overall actuarial survival (OS), progression-free survival (PFS), and infield-failure-free survival (IFFS) analyses were performed by Kaplan-Meier method. A Cox proportional hazards model was used for univariate and multivariate analysis. Pearson's chi-square test or Fisher's exact test was used to compare patient characteristics and treatment-related toxicity between the groups. RESULTS: Sixty-five patients were treated with IG-IMRT and 122 patients with 3D-CRT. No significant differences were seen between the groups for all patient characteristics. IG-IMRT delivered higher doses than 3D-CRT (median biological effective dose 62.5 vs 53.1 Gy, P < 0.001). IG-IMRT showed significantly higher 3-year OS (33.4 vs 13.5 %, P < 0.001), PFS (11.1 vs 6.0 %, P = 0.004), and IFFS (46.8 vs 28.2 %, P = 0.007) than 3D-CRT. On univariate and multivariate analysis, RT modality was significant prognostic factor for OS (HR 2.18; 95 % CI 1.45-3.25; P < 0.001), PFS (HR 1.64; 95 % CI 1.17-2.29; P = 0.004). There was no significant difference between the two modalities for radiation-induced liver disease (P = 0.716). CONCLUSION: Our findings suggest that IG-IMRT could be an effective treatment that provides survival benefit without increasing severe toxicity in locally advanced HCC.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1595~1605-
dc.relation.isPartOfJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHCarcinoma, Hepatocellular/mortality-
dc.subject.MESHCarcinoma, Hepatocellular/radiotherapy*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/mortality-
dc.subject.MESHLiver Neoplasms/radiotherapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRadiotherapy Planning, Computer-Assisted/methods-
dc.subject.MESHRadiotherapy, Conformal/methods-
dc.subject.MESHRadiotherapy, Image-Guided/methods-
dc.subject.MESHRadiotherapy, Intensity-Modulated/methods-
dc.titleImproved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pharmacology (약리학)-
dc.contributor.googleauthorHong In Yoon-
dc.contributor.googleauthorIk Jae Lee-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorJinsil Seong-
dc.identifier.doi10.1007/s00432-014-1697-0-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01956-
dc.contributor.localIdA03055-
dc.contributor.localIdA04268-
dc.contributor.localIdA04777-
dc.relation.journalcodeJ01283-
dc.identifier.eissn1432-1335-
dc.identifier.pmid24809934-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00432-014-1697-0-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordImage-guided radiotherapy-
dc.subject.keywordIntensity-modulated radiotherapy-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameYoon, Hong In-
dc.contributor.alternativeNameLee, Ik Jae-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorLee, Ik Jae-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorYoon, Hong In-
dc.rights.accessRightsfree-
dc.citation.volume140-
dc.citation.number9-
dc.citation.startPage1595-
dc.citation.endPage1605-
dc.identifier.bibliographicCitationJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.140(9) : 1595-1605, 2014-
dc.identifier.rimsid39422-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.